Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
- 25 November 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 5 (2) , 74-75
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic ReviewAmerican Journal of Kidney Diseases, 2008
- The role of aldosterone blockade in murine lupus nephritisArthritis Research & Therapy, 2008
- The incidence and implications of aldosterone breakthroughNature Clinical Practice Nephrology, 2007
- Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactoneAmerican Journal of Physiology-Renal Physiology, 2007
- Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicityAmerican Journal of Physiology-Renal Physiology, 2007
- Plasma Aldosterone Is Independently Associated With the Metabolic SyndromeHypertension, 2006
- Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicityAmerican Journal of Physiology-Renal Physiology, 2005
- Aldosterone-Induced Organ Damage: Plasma Aldosterone Level and Inappropriate Salt StatusHypertension Research, 2004
- Aldosterone Antagonism Attenuates Obesity-Induced Hypertension and Glomerular HyperfiltrationHypertension, 2004
- Aldosterone in Chronic Kidney and Cardiac DiseaseJournal of the American Society of Nephrology, 2003